Paraoxonases (PONs) may exert anti-atherogenic action by reducing lipid peroxidation. We evaluated the influence of 2 polymorphisms within PON1 (192 Gln/ Arg) and PON2 (311 Ser/Cys) genes in 407 young Poles: 273 patients who experienced a first myocardial infarction (MI) under the age of 45 (study group) and 134 healthy volunteers (control group) with a HEART Score ≤2 (low risk). Paraoxonase 1 polymorphism 192Gln/Arg influenced the risk of premature MI (P = .0054). A positive family history of coronary artery disease (CAD) was associated with the 192Arg allele (P = .0107). The association between PON1 genotype (192 Gln/Arg) and low-density lipoprotein cholesterol (LDL-C) (P = .036) levels was also observed. However, we did not find any relationship between polymorphism 311Ser/Cys and CAD risk (P = .418). PON1 polymorphism 192Gln/Arg influenced the risk of premature MI. The association between PON1 genotype (192 Gln/Arg) and serum LDL-C levels may be explained by PON participation in reverse cholesterol transport.
Ng CJ, Wadleigh DJ, Gangopadhyay A., et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem. 2001 ;276(48):44444-44449.
3.
Primo-Parmo SL, Hsu C., Law DJ, La Du BNLocation and arrangement of three paraoxonase genes: PON1, PON2 and PON3, on human chromosome 7. Am J Hum Genet.1996;59 (suppl):A406.
4.
Guxens M., Tomás M., Elosua R., et al., and the Investigadores del Estudio IBERICA.Association between paraoxonase-1 and paraoxonase-2 polymorphisms and the risk of acute myocardial infarction [in Spanish]. Rev Esp Cardiol.2008;61(3):269-275.
5.
Sanghera DK, Aston CE, Saha N., Kamboh MIDNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet. 1998;62(1):36-44.
6.
Mackness B., Durrington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107(22): 2775-2779.
7.
Bielecka-Dabrowa A., Barylski M., Mikhailidis DP, Rysz J., Banach M.HSP 70 and atherosclerosis-protector or activator? Expert Opin Ther Targets. 200913(3): 307-317.
8.
Gluba A., Banach M., Mikhailidis DP, Rysz J.Genetic determinants of cardiovascular disease. In Vivo. 2009;23(5):797-812.
9.
Watson AD, Berlinor JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein . J Clin Invest. 1995;96(6): 2882-2891.
10.
Aviram M., Rosenblat M., Bisgaier CL, Newton SL, Primo-Parmo SL, La Du BNParaoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest.1998;101(8):1581-1590.
11.
Robertson KS , Hawe E., Miller GJ, Talmud PJ, Humphries SE, and the Northwick Park Heart Study II.Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim Biophys Acta. 2003 ;1639(3):203-212.
12.
Rosenblat M. , Gaidukov L., Khersonsky O., et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem. 2006;281(11):7657-7665.
13.
Davies HG, Rebecca JR, Keifer M., Broomfield CA, Sowalla J., Furlong CEThe effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet. 1996;14(3):334-336.
14.
Roy AC, Saha N., Tay JS, Ratnam SSSerum paraoxonase polymorphism in three populations of Southeast Asia. Hum Hered. 1991;41(4):265-269.
15.
Rosenblat M. , Karry R., Aviram M.Paraoxonase-1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis . 2008;187(1):74.e1-74.e10.
16.
Senti M., Tomás M., Vila J., et al. Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase1 gene: the REGI-COR study. Atherosclerosis. 2001;156(2):443-449.
17.
James RW, Leviev I., Righetti A.Smoking is associated with reduced serum paraoxonase activity and concentration in patient with coronary artery disease. Circulation. 2000;101(19):2252-2257.
18.
McElveen J. , Mackness MI, Colley CM, Peard T., Warner S., Walker CHDistribution of paraoxonase hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem. 1986;32(4):671-673.
19.
Senti M., Tomás M., Marrugat J., Elosua R., for the REGI-COR Investigators.Paraoxonase1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs. Arterioscler Thromb Vasc Biol. 2001;21(3):415-420.
20.
Mackness MI , Harty D., Bhatnagar D., et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991;86(2-3):193-199.
21.
Aviram M., Billicke S., Sorenson S., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol. 1998;18(10): 1617-1624.
22.
Aviram M., Hardak E., Vaya J., et al. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid arteriosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000;101(21):2510-2517.
23.
Mackness B. , Mackness MI, Arrol S., Turkie W., Durrington PNEffect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett . 1998;423(1):57-60.
24.
Mackness MI, Arrol S., Mackness B., Durrington PNThe alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation . Lancet. 1997; 349(9055):851-852.
25.
Ruiz J., Blanche H., James RW, et al. Gln/Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995;346(8979):869-872.
26.
Zama T., Murata M., Matsubara Y., et al. A 192 Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese . Arterioscler Thromb Vasc Biol. 1997;17(12):3565-3569.
27.
Hegele RA, Brunt JH, Connelly PWA polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol. 2005;15(1):89-95.
28.
Leus FR, Zwart M., Kastelein JJ, Voorbij HAPON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis . 2001;154(3):641-649.
29.
Mainous AG 3rd , Koopman RJ, Diaz VA, Everett CJ, Wilson PW, Tilley BCA coronary heart disease risk score based on patient-reported information. Am J Cardiol.2007;99(9):1236-1241.
30.
Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/ American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J.2000; 21(18):1502-1513.
31.
Gluba A., Banach M., Rysz J., Piotrowski G., Fendler W., Pietrucha T.Is polymorphism within eNOS gene associated with the late onset of myocardial infarction? A Pilot Study. Angiology. in press.
32.
Sambrook JE, Fritsch F., Maniatis T.Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor; 1989.
33.
Pfohl M., Koch M., Enderle MD, et al. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. 1999;48(3):623-627.
34.
Su S., Chen JH, Huang JF, et al. Paraoxonase gene cluster variations associated with coronary heart disease in Chinese Han women. Chin Med J. 2005;118(14): 1167-1174.
35.
Antikainen M., Murtomaki S., Syvanne M., et al. The Gln/ Arg 192 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of the coronary artery disease in Finns. J Clin Invest. 1996 ;98(4): 883-885.
36.
Ombres D., Pannitteri G., Montali A., et al. The Gln/ Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol. 1998;18(10): 1611-1616.
37.
Jalilian A. , Javadi E., Akrami M., et al. Association of cys 311 ser polymorphism of paraoxonase-2 gene with the risk of coronary artery disease. Arch Iran Med. 2008; 11(5):544-549.
38.
van Himbergen TM, Roest M., de Graaf J., et al. Indications for a contribution of paraoxonase type-1 to plasma high-density lipoprotein levels in patients with familial hypercholesterolemia. J Lipid Res. 2005;46(3):445-451.
39.
Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000;275(23):17527-17535.
40.
Chen Q., Reis SE, Kammerer CM, et al., for the WISE Study Group.Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored women’s ischemia syndrome evaluation (WISE) study. Am J Hum Genet. 2003;72(1):13-22.
41.
Fuhrman B., Volkova N., Aviram M.Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and paraoxonase. Atherosclerosis. 2002;161(2):307-316.
42.
Rozenberg O. , Shih DM, Aviram M.Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis. Possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol. 2003;23(3):467-467.
43.
Rosenblat M. , Vaya J., Shih D., Aviram M.Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine . Atherosclerosis. 2005; 179(1):69-77.
44.
Rozek LS, Hatsukami TS, Richter RJ, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J Lipid Res. 2005;46(9):1888-1895.
45.
Hegele RA, Brunt JH, Connelly PWA polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol. 1995;15(1):89-95.
46.
Nevin DN, Zambon A., Furlong CE, Richter RJ, Humbert R., Hokanson JEParaoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol. 1996;16(10):1243-1249.
47.
Saha N., Roy AC, Teo SH, Tay JS, Ratnam SSInfluence of serum paraoxonase polymorphism on serum lipids and apolipoproteins . Clin Genet. 1991;40(4):277-282.
48.
Blatter MC, James RW, Messmer S., Barja F., Pometta D.Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45Identity of K-45 with paraoxonase.. Eur J Biochem. 1993;211(3):871-879.
49.
Oda MN, Bielicki JK, Ho TT, Berger T., Rubin EM, Forte TMParaoxonase 1 overexpression in mice and its effect on high-density lipoproteins . Biochem Biophys Res Commun. 2002;290(3):921-927.
50.
Schaefer EJ, Zech LA, Jenkins LL, et al. Human apolipoprotein A-I and A-II metabolism. J Lipid Res. 1982; 23(6):850-862.
51.
Kuivenhoven JA , Pritchard H., Hill J., Frohlich J., Assmann G., Kastelein J.The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndrome. J Lipid Res. 1997;38(2):191-205.
Bielicki JK, Forte TMEvidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity. J Lipid Res. 1999;40(5):948-954.
54.
Brousseau ME , Santamarina-Fojo S., Vaisman BL, et al. Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner . J Lipid Res.1997;38(12): 2537-2547.
55.
Wang M., Briggs MRHDL: the metabolism, function, and therapeutic importance. Chem Rev. 2004;104(1): 119-137.
56.
Fruchart JCHDL subclasses impact of metabolic and therapeutic interventions. Atherosclerosis. 1997;146 (Suppl. 1):S14.
57.
Kanjilal S. , Shanker J., Rao VS, Mukherjee M., Iyengar SS, Kakkar VVAssociation of metabolic syndrome with atherothrombotic blood phenotypes in Asian Indian families with premature coronary artery disease . Arch Med Sci. 2008;4(2):145-151.
58.
Boer JM, Feskens EJ, Kuivenhoven JA, et al. Parental history of myocardial infarction: lipid tratis, gene polymorphins and lifestyle. Atherosclerosis. 2001;155(1): 149-156.
59.
Colditz GA, Rimm EB, Giovannucci E., Stampfer MJ, Rosner B., Willett WCA prospective study of parental history of myocardial infarction and coronary artery disease in men. Am J Cardiol. 1991;67(11):933-938.
60.
Zielaskowska J., Olszewska-Slonina D.The polymorphism of paraoxonase and its effects in physiological and pathological processes. Adv Clin Exp Med. 2006;15(6): 1073-1078.
61.
Zimmermann AV, Doehner W., Pérez AV, et al. The relationship between high-density lipoprotein, bacterial lipopolysaccharide, and tumour necrosis factor-α in patients with acute decompensated heart failure. Arch Med Sci. 2008;4(4):380-385.
62.
Gnasso A., Motti C., Irace C., et al. The Arg allele in position 192 of PON1 is associated with carotid atherosclerosis in subjects with elevated HDLs. Atherosclerosis . 2002;164(2):289-295.
63.
Piestrzeniewicz K., Łuczak K., Maciejewski M., Goch JHImpact of obesity and adipokines on cardiac structure and function in men with first myocardial infarction. Arch Med Sci. 2008;4(2):152-160.
64.
Lagos KG, Filippatos TD, Tsimihodimos V., et al. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids. 2009;44(1):9-16.
65.
Heusch P., Skyschally A., Leineweber K., Haude M., Erbel R., Heusch G.The interaction of coronary microembolization and ischemic preconditioning: a third window of cardioprotection through TNF-alpha. Arch Med Sci. 2007;3(2):83-92.
66.
Florentin M. , Liberopoulos EN, Wierzbicki AS, Mikhailidis DPMultiple actions of high-density lipoprotein . Curr Opin Cardiol. 2008;23(4):370-378.
67.
Poulakou MV , Paraskevas KI, Vlachos IS, et al. Effect of statins on serum apolipoprotein j and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. Angiology. 2008;59(2):137-144.
